Evidence map›Paper›PMID 30265352›Full record

ArticleProtein engineering, design & selection : PEDS2018

Contribution of an unusual CDR2 element of a single domain antibody in ricin toxin binding affinity and neutralizing activity.

Michael J Rudolph, David J Vance, Simon Kelow, Siva Krishna Angalakurthi, Sophie Nguyen, Simon A Davis, Yinghui Rong, C Russell Middaugh, David D Weis, Roland Dunbrack and 2 more

Abstract read
In one paragraph

Article in Protein engineering, design & selection : PEDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Michael J RudolphNew York Structural Biology Center, New York, NY, USA.
David J VanceDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
Simon KelowDepartment of Biochemistry and Molecular Biophysics Graduate Group, University of Pennsylvania, Philadelphia, PA, USA.
Siva Krishna AngalakurthiDepartment of Pharmaceutical Chemistry and Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, KS, USA.
Sophie NguyenNew York Structural Biology Center, New York, NY, USA.
Simon A DavisNew York Structural Biology Center, New York, NY, USA.
Yinghui RongDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
C Russell MiddaughDepartment of Pharmaceutical Chemistry and Macromolecule and Vaccine Stabilization Center, University of Kansas, Lawrence, KS, USA.
David D WeisDepartment of Chemistry and Ralph Adams Institute for Bioanalytical Chemistry, University of Kansas, Lawrence, KS, USA.
Roland DunbrackInstitute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.
John KaranicolasInstitute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA, USA.
Nicholas J MantisDivision of Infectious Diseases, Wadsworth Center, New York State Department of Health, Albany, NY, USA.
New York Structural Biology Center · US

Funding

Structural Bioinformatics of Proteins and Protein Complexes and Applications to Cancer BiologyR35GM122517 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI ROLAND L DUNBRACK · 2017 to 2026
$6.3M
Development of methods for antibody computational designR01GM111819 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI DUNBRACK, ROLAND L · 2015 to 2016
$700k
NIAID NIH HHS HHSN272201400021CNIGMS NIH HHS R01 GM111819NIGMS NIH HHS R35 GM122517
6 · The paper itself

Abstract

Ricin toxin's enzymatic subunit (RTA) has been subjected to intensive B cell epitope mapping studies using a combination of competition ELISAs, hydrogen exchange-mass spectrometry and X-ray crystallography. Those studies identified four spatially distinct clusters (I-IV) of toxin-neutralizing epitopes on the surface of RTA. Here we describe A9, a new single domain camelid antibody (VHH) that was proposed to recognize a novel epitope on RTA that straddles clusters I and III. The X-ray crystal structure of A9 bound to RTA (2.6 Å resolution) revealed extensive antibody contact with RTA's β-strand h (732 Å2 buried surface area; BSA), along with limited engagement with α-helix D (90 Å2) and α-helix C (138 Å2). Collectively, these contacts explain the overlap between epitope clusters I and III, as identified by competition ELISA. However, considerable binding affinity, and, consequently, toxin-neutralizing activity of A9 is mediated by an unusual CDR2 containing five consecutive Gly residues that interact with α-helix B (82 Å2), a known neutralizing hotspot on RTA. Removal of a single Gly residue from the penta-glycine stretch in CDR2 reduced A9's binding affinity by 10-fold and eliminated toxin-neutralizing activity. Computational modeling indicates that removal of a Gly from CDR2 does not perturb contact with RTA per se, but results in the loss of an intramolecular hydrogen bond network involved in stabilizing CDR2 in the unbound state. These results reveal a novel configuration of a CDR2 element involved in neutralizing ricin toxin.

Indexed as

Antibody AffinityAmino Acid SequenceAnimalsAntibodies, NeutralizingChlorocebus aethiopsModels, MolecularProtein Structure, SecondaryRicinSingle-Domain AntibodiesVero CellsAntibodies, NeutralizingRicinSingle-Domain Antibodies

Identifiers

PMID30265352
PMCPMC6277176
OpenAlexW2894199489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.